FDA accelerated approval of anticancer agents

被引：0

|

作者：

Ning, Y. M.

Johnson, J. R.

Farrell, A. T.

Maher, V. E.

Justice, R. L.

Pazdur, R.

机构：

[1] NCI, US FDA, Silver Spring, MD USA

[2] US FDA, Silver Spring, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.6065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6065

引用

收藏

页数：1

相关论文

共 50 条

[1] FDA accelerated approval under scrutiny
不详
[J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (06) : 290 - 290
[2] FDA accelerated approval benefits glioblastoma
Cloughesy, Timothy
[J]. LANCET ONCOLOGY, 2010, 11 (12): : 1120 - 1120
[3] FDA granted accelerated approval to ibrutinib(IMBRUVICA)
[J]. Journal of Chinese Pharmaceutical Sciences, 2014, (04) : 273 - 273
[4] The FDA Accelerated Drug Approval Program Explained
不详
[J]. US PHARMACIST, 2023, 48 (10) : 56 - 57
[5] FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer
Gyawali, Bishal
Kesselheim, Aaron S.
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (07) : 397 - 398
[6] FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer
Bishal Gyawali
Aaron S. Kesselheim
[J]. Nature Reviews Clinical Oncology, 2021, 18 : 397 - 398
[7] Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Hwang, T.
Molto, C.
Puy, M. Borrell
Tibau, A.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S931 - S931
[8] Surrogate endpoints and FDA's accelerated approval process
Fleming, TR
[J]. HEALTH AFFAIRS, 2005, 24 (01) : 67 - 78
[9] Modernising the US FDA's Accelerated Approval pathway
Benjamin, David J.
Lythgoe, Mark P.
[J]. LANCET ONCOLOGY, 2023, 24 (03): : 203 - 205
[10] Accelerated Approval - Taking the FDA's Concerns Seriously
Sachs, Rachel E.
Donohue, Julie M.
Dusetzina, Stacie B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 199 - 203

← 1 2 3 4 5 →